Literature DB >> 101847

Individual variation in the production and survival of F cells in sickle-cell disease.

G J Dover, S H Boyer, S Charache, K Heintzelman.   

Abstract

The protective role and underlying sources of the elevated levels of fetal hemoglobin associated with sickle-cell anemia were reassessed by microscopical immunodiffusion assays. Three variables that contribute to levels of fetal hemoglobin were examined: the percentage of fetal-hemoglobin-containing reticulocytes produced; the quantity of fetal hemoglobin synthesized within such cells; and the extent to which the fraction of fetal-hemoglobin-bearing erythrocytes is enriched beyond the level produced. Four general findings emerged from analysis of 29 patients: each variable is separately regulated; the expression of each is often distinctly different between individual patients; contrary to prior speculation, production of fetal hemoglobin may be as great in the absence of heterocellular hereditary persistence of the hemoglobin as in its presence; and fetal hemoglobin does not, as often supposed, guarantee preferential cell survival. We conclude that the differences encountered among patients must reflect heterogeneity among factors that modify production and survival of cells bearing fetal hemoglobin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 101847     DOI: 10.1056/NEJM197812282992603

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  34 in total

1.  The effect of fetal hemoglobin on the survival characteristics of sickle cells.

Authors:  Robert S Franco; Zahida Yasin; Mary B Palascak; Peter Ciraolo; Clinton H Joiner; Donald L Rucknagel
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

Review 2.  Pharmacological modification of hemoglobin F expression in sickle cell anemia: an update on hydroxyurea studies.

Authors:  S Charache
Journal:  Experientia       Date:  1993-02-15

3.  Time-dependent changes in the density and hemoglobin F content of biotin-labeled sickle cells.

Authors:  R S Franco; J Lohmann; E B Silberstein; G Mayfield-Pratt; M Palascak; T A Nemeth; C H Joiner; M Weiner; D L Rucknagel
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

4.  Alpha thalassemia changes erythrocyte heterogeneity in sickle cell disease.

Authors:  C T Noguchi; G J Dover; G P Rodgers; G R Serjeant; S E Antonarakis; N P Anagnou; D R Higgs; D J Weatherall; A N Schechter
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

Review 5.  Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders.

Authors:  Daniel E Bauer; Sophia C Kamran; Stuart H Orkin
Journal:  Blood       Date:  2012-08-17       Impact factor: 22.113

6.  5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin.

Authors:  R K Humphries; G Dover; N S Young; J G Moore; S Charache; T Ley; A W Nienhuis
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

7.  Quantification of whole-brain oxygenation extraction fraction and cerebral metabolic rate of oxygen consumption in adults with sickle cell anemia using individual T2 -based oxygenation calibrations.

Authors:  Wenbo Li; Xiang Xu; Peiying Liu; John J Strouse; James F Casella; Hanzhang Lu; Peter C M van Zijl; Qin Qin
Journal:  Magn Reson Med       Date:  2019-09-04       Impact factor: 4.668

8.  Cellular mechanisms for increased fetal hemoglobin production in culture. Evidence for continuous commitment to fetal hemoglobin production during burst formation.

Authors:  G J Dover; M Ogawa
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

Review 9.  Fetal hemoglobin in sickle cell anemia.

Authors:  Martin H Steinberg
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

10.  Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.

Authors:  R Borba; C S P Lima; H Z W Grotto
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.